	US 12,285,484 B2
	Cancer associated antibody compositions and methods of use
Daniele Biasci, Cambridge, MA (US); Ines De Santiago Domingos De Jesus, Cambridge, MA (US); and Berke Cagkan Toptas, Cambridge, MA (US)
Assigned to ABSCI CORPORATION, Vancouver, WA (US)
Appl. No. 17/277,214
Filed by Absci Corporation, Vancouver, WA (US)
PCT Filed Sep. 19, 2019, PCT No. PCT/US2019/051967 § 371(c)(1), (2) Date Mar. 17, 2021, PCT Pub. No. WO2020/061337, PCT Pub. Date Mar. 26, 2020.
Claims priority of provisional application 62/733,444, filed on Sep. 19, 2018.
Claims priority of provisional application 62/733,443, filed on Sep. 19, 2018.
Claims priority of provisional application 62/733,435, filed on Sep. 19, 2018.
Prior Publication US 2022/0031841 A1, Feb. 3, 2022
Int. Cl. A61K 39/39 (2006.01); A61K 39/395 (2006.01); A61K 45/06 (2006.01); A61N 5/10 (2006.01); A61P 35/00 (2006.01); C07K 14/725 (2006.01); C07K 16/18 (2006.01); C07K 16/24 (2006.01); C07K 16/26 (2006.01); C07K 16/30 (2006.01); C07K 16/40 (2006.01); G01N 33/574 (2006.01)

CPC A61K 39/39575 (2013.01) [A61K 45/06 (2013.01); A61N 5/10 (2013.01); A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 16/18 (2013.01); C07K 16/244 (2013.01); C07K 16/26 (2013.01); C07K 16/30 (2013.01); C07K 16/3069 (2013.01); C07K 16/40 (2013.01); G01N 33/57484 (2013.01); A61N 2005/1098 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01)]

17 Claims

1. An antibody or antigen-binding fragment thereof comprising:

a complementarity-determining region heavy chain 1 (CDR-H1), a CDR-H2 and a CDR-H3, wherein the CDR-H1 comprises the reconstructed polypeptide consensus sequence set out in SEQ ID NO: 95, the CDR-H2 comprises the reconstructed polypeptide consensus sequence set out in SEQ ID NO: 67, and the CDR-H3 comprises the reconstructed polypeptide consensus sequence set out in SEQ ID NO: 39; and

a complementarity-determining region light chain 1 (CDR-L1), a CDR-L2 and a CDR-L3, wherein the CDR-L1 comprises the reconstructed polypeptide consensus sequence set out in SEQ ID NO: 109, the CDR-L2 comprises the reconstructed polypeptide consensus sequence set out in SEQ ID NO: 81, and the CDR-L3 comprises the reconstructed polypeptide consensus sequence set out in SEQ ID NO: 53.